Oligo Medic
Oligo Medic is a Canadian biomaterials company that develops chitosan-based biopolymer technologies for orthopedic applications, commercializing the JointRep® injectable cartilage-repair hydrogel across 30+ countries while advancing the LOMU® viscosupplementation pipeline.
- Company typePrivate
- Founded2010
- HeadquartersLaval, Canada
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Oligo Medic does
Oligo Medic is a privately held Canadian biomaterials company headquartered in Laval, Quebec, founded in 2010 by biomaterials experts. The company specializes in functional biopolymers derived from chitosan and its derivatives, developing hydrogels, nanoparticles, photocuring materials, and bio-inks for biomedical applications with a focus on orthopedic use cases.
The company's core commercial asset is JointRep®, an arthroscopically injectable thermo-gel hydrogel scaffold designed to enhance outcomes of bone marrow stimulation procedures for cartilage repair. JointRep® is approved by Australia's Therapeutic Goods Administration (TGA) and regulators in multiple other countries but is not currently available in the United States. A second product, LOMU®, is a viscosupplementation formulation positioned as a longer-residence-time alternative to hyaluronic acid injections and is in pre-clinical validation. Underlying these products is a broader chitosan-derivative technology platform spanning self-healing gels, polysaccharide-based nanoparticles for drug and genetic-material delivery, photocuring systems, and bio-inks for tissue engineering constructs.
Oligo Medic generates revenue primarily through medical device sales of JointRep® distributed via an established commercialization network covering more than 30 countries, supplemented by potential licensing of its proprietary biopolymer technologies derived from 25+ years of research. Go-to-market is executed through orthopedic-specialized field sales targeting surgeons, sports medicine physicians, and hospitals, supported by clinical evidence generation via the JMAC Study enrolling patients across Australia and Canada. Pricing is not publicly disclosed and operates on quote-based enterprise contracts with healthcare institutions.
Oligo Medic firmographics
Firmographics- Name
- Oligo Medic
- Legal name
- Oligo Medic
- Website
- https://oligomedic.com
- Company type
- Private
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Oligo Medic is a Canadian biomaterials company that develops chitosan-based biopolymer technologies for orthopedic applications, commercializing the JointRep® injectable cartilage-repair hydrogel across 30+ countries while advancing the LOMU® viscosupplementation pipeline.
- Ownership category
- akta.pro rank
Oligo Medic industry classification
Industry- Product category
- Orthopedic Medical Devices
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG)
- akta.pro secondary industry
- Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE)
Keywords
Where Oligo Medic is headquartered
LocationHeadquarters
- HQ city
- Laval
- HQ country
- Canada
- HQ region
- North America
Offices1 record
Markets served
Oligo Medic business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
Revenue model
- Medical Device Product Sales: Sale of approved medical devices including JointRep® thermo-gel scaffold for cartilage repair. Commercialized through distribution network covering more than 30 countries.
- LOMU® Viscosupplementation (Pipeline): Future viscosupplementation product for osteoarthritis treatment, currently in pre-clinical validation stage.
- Technology Licensing: Licensing of proprietary biopolymer technologies and formulations developed from 25+ years of research in chitosan derivatives for various biomedical applications.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels5 records
Oligo Medic product offering
Product offeringCore offering
Oligo Medic develops and commercializes chitosan-based biopolymer medical devices for orthopedic applications. Its marketed product, JointRep®, is an arthroscopically injectable thermo-gel hydrogel scaffold designed to enhance outcomes of bone marrow stimulation procedures for cartilage repair. The company's pipeline includes LOMU®, a viscosupplementation formulation intended as a longer-residence-time alternative to hyaluronic acid injections for joint lubrication.
Product overview
Oligo Medic is a biomaterials company specializing in orthopedic applications of biopolymers, founded in 2010. The company offers a portfolio centered on chitosan-based technologies for cartilage repair and joint lubrication. The core marketed product is JointRep®, an injectable hydrogel scaffold for cartilage repair, while LOMU® is a pre-clinical viscosupplementation formulation. Underlying these products are proprietary technology platforms including Self-Healing Gel, Nanoparticles (for drug delivery), Photocuring, and Bio-ink, all built on chitosan biopolymer chemistry. The company operates across more than 30 countries through a commercialization network.
Differentiator
Problem solved
Functional benefit
Brands
- JointRep: Arthroscopically injectable hydrogel scaffold designed to enhance outcomes of bone marrow stimulation procedure for cartilage repair. Approved for use by Therapeutic Goods Administration in Australia and multiple other countries. Not currently available in the United States.
- LOMU
Products and services
- JointRep®
Quantifiable outcome
- Cartilage defects occur in more than 900,000 injuries per year in the US alone
- +1 more outcomes
Companies that use Oligo Medic
Customer profileNamed customers8 records
Segments3 records
Ideal customer profiles2 records
Oligo Medic technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature7 records
Oligo Medic partnerships and signals
Strategic signalScale indicators4 records
Recent moves5 records
Expansion highlights5 records
Oligo Medic competitors and assessment
Company assessmentDirect peers
- Anika Therapeutics: Anika produces hyaluronic acid-based viscosupplementation products (e.g., Monovisc, Orthovisc) for osteoarthritis joint lubrication. Direct competitor to Oligo Medic's pipeline LOMU® product, which is positioned as an alternative to HA injections.
- Bioventus: Bioventus markets DUROLANE and other HA-based viscosupplements for osteoarthritis treatment, plus orthopedic biologics for cartilage repair. Direct competitor across Oligo Medic's viscosupplementation and cartilage repair portfolio.
- CartiHeal (Smith & Nephew): CartiHeal (acquired by Smith & Nephew) developed Agili-C, a cartilage repair scaffold for osteochondral lesions. Direct competitor to JointRep® in the cartilage regeneration scaffold market.
- Ferring Pharmaceuticals: Ferring markets EUFLEXXA (hyaluronic acid viscosupplement) for osteoarthritis knee pain. Direct competitor in the viscosupplementation space that LOMU® would target.
- Vericel Corporation: Vericel markets MACI (autologous chondrocyte implantation), the leading FDA-approved cartilage repair product. Direct competitor to Oligo Medic's JointRep® in the cartilage repair market, though addressing different procedural approaches (cell therapy vs. hydrogel scaffold-enhanced microfracture).
Broad incumbents
- Smith & Nephew: Smith & Nephew is a major orthopedic medical device company with products across cartilage repair, sports medicine, and viscosupplementation. Their Regenaflex (hyaluronic acid) and broader sports medicine portfolio overlap with both JointRep® and LOMU® markets.
- Stryker Corporation: Stryker is a diversified orthopedic medical device leader with sports medicine and joint preservation products relevant to cartilage repair procedures. Larger incumbent operating broadly across Oligo Medic's target orthopedic segments.
- Sanofi (Genzyme): Sanofi markets Synvisc/Synvisc-One, one of the most widely used HA viscosupplementation brands globally. As a large incumbent in viscosupplementation, Sanofi represents the dominant commercial competitor that LOMU® would need to displace.
Peers
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Oligo Medic social profiles
Digital presenceOligo Medic compliance and trust
Trust signalCompliance1 record
Oligo Medic financial estimates
Financial estimateRevenue estimate
Valuation estimate
Oligo Medic leadership team
Management profileNumber of profiles
Profiles11 records
Oligo Medic funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Oligo Medic M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Oligo Medic
What does Oligo Medic do?
Oligo Medic develops and commercializes chitosan-based biopolymer medical devices for orthopedic applications. Its marketed product, JointRep®, is an arthroscopically injectable thermo-gel hydrogel scaffold designed to enhance outcomes of bone marrow stimulation procedures for cartilage repair. The company's pipeline includes LOMU®, a viscosupplementation formulation intended as a longer-residence-time alternative to hyaluronic acid injections for joint lubrication.
Is Oligo Medic a public or private company?
Oligo Medic is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Oligo Medic founded?
Oligo Medic was founded in 2010. It employs 11 to 50 people.
Where is Oligo Medic based?
Oligo Medic is headquartered in Laval, Canada, in the North America region.
How does Oligo Medic make money?
Three revenue lines are on record. Medical Device Product Sales are the primary driver. The others are LOMU® Viscosupplementation (Pipeline) and technology Licensing.
Who are Oligo Medic's main competitors?
Direct peers on record are Anika Therapeutics, Bioventus, CartiHeal (Smith & Nephew), Ferring Pharmaceuticals and Vericel Corporation. Broad incumbents are Smith & Nephew, Stryker Corporation and Sanofi (Genzyme). Histogenics (now part of Ocugen) is listed as a peer.
Does Oligo Medic have an API?
No public API is recorded for Oligo Medic.
What industry is Oligo Medic in?
Oligo Medic's product category is Orthopedic Medical Devices. Its primary akta.pro industry code is HLAHAEAG, Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM), with a secondary code of HLAHALAE, Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts). Its NAICS code is 339113 and its SIC code is 3842.